Chemical Approaches to Reducing Tau Levels
Dr. Jason E. Gestwicki and his team recently uncovered a promising class of Hsp70-binding compounds and have shown that these compounds reduce tau accumulation in cellular and animal models of AD. The next major goal is to improve the safety and efficacy of these compounds before they are tested in human clinical trials.
These studies are designed to establish whether Hsp70 is a bona fide drug target for AD. The goal of this project is to produce a set of pre-clinical data that could, if successful, provide the rationale for advancing these compounds towards clinical trials.
About the Researcher
As of April 1, 2013, Dr. Gestwicki is the Associate Professor in the In Residence series at the Institute for Neurodegenerative Diseases (IND) and the Department of Pharmaceutical Chemistry at UCSF (formerly the William B. Pratt Collegiate Professor of the Life Sciences Institute and Associate Professor of Pathology and Biological Chemistry at the University of Michigan). He completed doctoral studies at University of Wisconsin and post-doctoral work at Stanford University. Dr. Gestwicki's laboratory uses the tools of organic chemistry to explore how molecular chaperones regulate protein misfolding and accumulation in neurodegenerative disorders. In addition to a BrightFocus award, Dr. Gestwicki has been funded by the National Institutes of Health and the National Science Foundation.
Dr. Gestwicki is originally from western New York State and completed undergraduate studies in chemistry at the State University of New York College at Fredonia. He started his independent research group at the University of Michigan in 2005 and is focused on finding new ways of treating Alzheimer's disease.
First published on: Tuesday, July 10, 2012
Last modified on: Wednesday, April 3, 2013